You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

Collagenase clostridium histolyticum-aaes - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for collagenase clostridium histolyticum-aaes
Tradenames:1
High Confidence Patents:0
Applicants:1
BLAs:1
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for collagenase clostridium histolyticum-aaes Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for collagenase clostridium histolyticum-aaes Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for collagenase clostridium histolyticum-aaes Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Collagenase Clostridium Histolyticum-aaes

Introduction to Collagenase Clostridium Histolyticum-aaes

Collagenase clostridium histolyticum-aaes (CCH) is a biologic drug that has garnered significant attention in recent years due to its efficacy in treating various fibrotic conditions. This enzyme, derived from the bacterium Clostridium histolyticum, is used to break down collagen, a protein that, when excessively deposited, can lead to conditions such as Dupuytren’s contracture, Peyronie’s disease, and cellulite.

Market Growth Drivers

Increasing Awareness and Prevalence of Fibrotic Diseases

The global market for collagenase clostridium histolyticum is driven by the rising awareness and prevalence of diseases such as Dupuytren’s contracture and Peyronie’s disease. These conditions are more common in older populations, and with the aging demographic, the demand for effective treatments is increasing[1][3].

Government Initiatives and Awareness Campaigns

Government initiatives and awareness campaigns play a crucial role in bolstering the market. As more people become aware of the available treatments, the demand for CCH is expected to rise. This increased awareness, particularly in regions like North America and Europe, is a significant driver for market growth[1].

Advancements in Healthcare Infrastructure

The presence of advanced healthcare infrastructure in regions such as North America and Europe further supports the growth of the CCH market. These regions have better access to diagnostic and treatment facilities, which enhances the adoption of CCH-based treatments[1][3].

Financial Trajectory

Market Size and Growth Rate

The collagenase clostridium histolyticum market is projected to experience moderate growth. By 2030, the market size is estimated to reach $725.93 million, growing at a Compound Annual Growth Rate (CAGR) of 3.20% from 2024 to 2030[3].

Regional Market Performance

  • North America: This region is expected to dominate the market due to the high prevalence of fibrotic diseases and the presence of advanced medical technologies. In 2021, North America accounted for the highest revenue share, with 36% of the overall market[3].
  • Europe: Europe is also anticipated to witness significant growth due to its well-developed healthcare infrastructure and increasing awareness about fibrotic diseases[1][3].
  • Asia Pacific: While the Asia Pacific region is expected to see moderate growth, it is hindered by a lack of complete awareness in developing economies such as India[1].
  • Middle East and Africa, Latin America: These regions are expected to witness slow growth due to the limited presence of well-established market players[1].

Competitive Landscape

The global collagenase clostridium histolyticum market is highly competitive, with several well-established players such as Smith & Nephew PLC, Endo Pharmaceuticals Inc., Healthpoint Ltd., Auxilium Pharmaceuticals Inc., and Advanced Biofactures Corporation. These companies are focusing on novel product launches and collaborations to expand their market presence and increase revenue shares[1].

Product Applications and Efficacy

Treatment of Fibrotic Conditions

CCH is primarily used to treat conditions like Dupuytren’s contracture and Peyronie’s disease. It is administered as a power-and-solvent injection kit to help remove the collagen deposits that cause these conditions[1].

Treatment of Cellulite

Recently, CCH has also been approved for the treatment of moderate to severe cellulite in the buttocks of adult women. Clinical trials have shown that CCH is effective in improving the appearance of cellulite, with significant improvements observed in both clinician and patient-reported scales[2].

Challenges and Restraints

High Production Costs

The production of CCH involves complex and expensive processes, including microbial fermentation, purification, and quality control. These high costs can be a significant restraint to market growth, as they are often passed on to end-users, making the enzyme an expensive reagent[4].

Regulatory Requirements

Stringent regulatory requirements for manufacturing biological products add to the costs and complexity of producing CCH. Compliance with these standards necessitates advanced technologies and rigorous testing procedures, which can be a barrier to entry for new market players[4].

Future Outlook

Research and Development

The future growth of the CCH market is heavily dependent on research and development activities aimed at producing safer, more cost-effective, and improved quality products. Investments in R&D are expected to drive innovation and expand the application scope of CCH[1][3].

Expanding Applications

The increasing focus on aesthetic improvements and the rising number of cosmetic surgeries also present opportunities for the CCH market. As collagenase enzymes are used in various cosmetic treatments, the growing demand for these procedures is likely to boost the market[4].

Key Takeaways

  • The collagenase clostridium histolyticum market is expected to grow moderately, driven by increasing awareness and prevalence of fibrotic diseases.
  • North America and Europe are poised to dominate the market due to advanced healthcare infrastructure and high disease prevalence.
  • High production costs and stringent regulatory requirements are significant challenges to market growth.
  • Research and development are crucial for producing safer and more cost-effective products.
  • Expanding applications in cosmetic treatments offer additional growth opportunities.

FAQs

What is collagenase clostridium histolyticum-aaes used for?

Collagenase clostridium histolyticum-aaes (CCH) is used to treat fibrotic conditions such as Dupuytren’s contracture, Peyronie’s disease, and moderate to severe cellulite in the buttocks of adult women.

Which regions are expected to dominate the CCH market?

North America and Europe are expected to dominate the CCH market due to the high prevalence of fibrotic diseases and advanced healthcare infrastructure.

What are the main challenges facing the CCH market?

The main challenges include high production costs, stringent regulatory requirements, and competitive pricing from alternative enzymes.

How is the CCH market expected to grow in the future?

The CCH market is expected to grow at a CAGR of 3.20% from 2024 to 2030, reaching a market size of $725.93 million by 2030.

What role does research and development play in the CCH market?

Research and development are crucial for producing safer, more cost-effective, and improved quality products, which will drive innovation and expand the application scope of CCH.

Sources

  1. Biospace: Collagenase Clostridium Histolyticum Market: Rising global awareness about diseases such as Peyronie’s is the key growth driver for the market.
  2. FDA: BLA Multidisciplinary Review and Evaluation BLA 761146 Qwo (collagenase clostridium histolyticum-aaes) for injection, for subcutaneous use.
  3. IndustryArc: Collagenase Clostridium Histolyticum Market Report, 2024-2030.
  4. Allied Market Research: Collagenase Market Size, Share and Growth Report, 2033.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.